Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) – Drugs In Development, 2024 report and make more profitable business decisions.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. These cells produce hormones that regulate various functions in the body. GEP-NETs can be classified as functional or non-functional, depending on whether they secrete excess hormones or not. Functional GEP-NETs can cause various syndromes, such as carcinoid syndrome, Zollinger-Ellison syndrome, or Verner-Morrison syndrome, depending on the type of hormone produced. Non-functional GEP-NETs may not cause any symptoms until they grow large or metastasize to other organs. The diagnosis of GEP-NETs is based on histopathology, immunohistochemistry, and hormonal assays. The treatment options include surgery, chemotherapy, radiotherapy, somatostatin analogues, peptide receptor radionuclide therapy, and targeted therapy. The prognosis of GEP-NETs depends on several factors, such as the tumor grade, stage, location, and functionality.
The Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) drugs in development market research report provide comprehensive information on the therapeutics under development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 35 molecules, with 34 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aadi Bioscience IncAbbVie Inc
Advanced Accelerator Applications SA
Akeso Inc
Ariceum Therapeutics GmbH
Beijing Sinotau Pharmaceutical Technology Co Ltd
Bristol-Myers Squibb Co
Camurus AB
Debiopharm International SA
Exelixis Inc
Grand Pharmaceutical Group Ltd
Hutchison MediPharma Ltd
Ipsen SA
ITM Isotope Technologies Munich SE
Jiangsu Hengrui Medicine Co Ltd
Merck & Co Inc
MimiVax LLC
Molecular Targeting Technologies Inc
Perspective Therapeutics Inc
Phanes Therapeutics Inc
Pharma Mar SA
RayzeBio Inc
Serene LLC
Shanghai Haihe Biopharma Co Ltd
Shanghai Jiao Tong University School of Medicine
TaiRx Inc
Teva Pharmaceutical Industries Ltd
Table of Contents
Table
Figures
Frequently asked questions